Afyx Therapeutics A/S
Public limited companyCVR 38793594HørsholmActive
Afyx Therapeutics A/S is a public limited company, based in Hørsholm, active in manufacture of pharmaceutical preparations, founded in 2017. After a loss in 2024, the company made a profit of DKK 1.5m in 2025. Equity grew to DKK 36.2m in 2025.
Key figures · financial year 2025
Gross profitDKK 23.1m−1.4% vs. 2024
Net profitDKK 1.5m+139.8% vs. 2024
EquityDKK 36.2m+274.5% vs. 2024
Employees13latest month from CVR
What has changed
calculated from recorded figures and datesFinancials: 2025 against 2024
- Gross profit fell 1% (2024 → 2025), to DKK 23.1m.
- Net profit went from a loss of DKK 3.8m to a profit of DKK 1.5m (2024 → 2025).
- Equity rose 275% (2024 → 2025), to DKK 36.2m.
Management and owners, last 24 months
- No longer registered as owner: Spexmac Holding ApS (03/12/2024).
Registrations, last 24 months
- 16/12/2024: Moved to Slotsmarken 11, 2970 Hørsholm
- 03/12/2024: Share capital changed from 18,831,752 DKK to 20,008,777 DKK
Calculated from the latest two annual reports in sequence and from registrations in CVR. A figure that is missing in either year gives no line, and we derive no figures.
Financial statements
Financial years 2020–2025 · amounts in DKK thousandEquity and net profit
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Change | |
|---|---|---|---|---|---|---|---|
| Revenue | not stated | not stated | not stated | not stated | not stated | not stated | – |
| Gross profit | −586 | 1,509 | −3,222 | 6,405 | 23,468 | 23,138 | −1.4% |
| Operating profit (EBIT) | −1,625 | −1,025 | −6,620 | −4,356 | −234 | 980 | +518.8% |
| Profit before tax | −1,690 | −1,186 | −6,719 | −4,646 | −1,576 | 1,518 | +196.3% |
| Net profit | −1,507 | −814 | −7,274 | −2,253 | −3,811 | 1,518 | +139.8% |
| Total assets | 6,095 | 9,776 | 13,407 | 15,826 | 15,463 | 40,861 | +164.3% |
| Equity | 4,696 | 6,243 | −1,031 | 4,741 | 9,660 | 36,178 | +274.5% |
| Liabilities | 1,399 | 3,533 | 14,438 | 6,981 | 5,803 | 4,682 | −19.3% |
| Cash and cash equivalents | 223 | 854 | 5,665 | 2,899 | 1,533 | 13,038 | +750.3% |
| Average number of employees | 2 | 2 | 3 | 5 | 11 | 5 | −54.5% |
Source: annual reports filed with the Danish Business Authority (XBRL). Figures for the company (not the group); change is the latest year against the year before. “–” means the figure is not stated in the annual report. Revenue is not stated for 2020, 2021, 2022, 2023, 2024, 2025: smaller companies may omit it, and we do not derive it from other figures.
Download the figures as CSV · free with an account, amounts in whole DKK
Signals from the financial statements
calculated from the 2025 figuresFewer employees
The number of employees fell 55% from 11 in 2024 to 5 in 2025.
How is this calculated?
The number of employees according to the annual report has fallen by at least 25%, and was at least 10 the year before.
The signals are rules applied to the figures in the annual reports. They are not an assessment or credit rating of the company. See Data and method.
Annual reports
6 financial years| Financial year | Period | Published | Figures for | Documents |
|---|---|---|---|---|
| 2025 | 01/01/2025 – 31/12/2025 | 25/09/2026 | The company | PDF not statedXBRL |
| 2024 | 01/01/2024 – 31/12/2024 | 27/05/2025 | The company | PDFXBRL |
| 2023 | 01/01/2023 – 31/12/2023 | 16/04/2024 | The company | PDFXBRL |
| 2022 | 01/01/2022 – 31/12/2022 | 22/05/2023 | The company | PDFXBRL |
| 2021 | 01/01/2021 – 31/12/2021 | 28/06/2022 | The company | PDFXBRL |
| 2020 | 01/01/2020 – 31/12/2020 | 06/05/2021 | The company | PDFXBRL |
The figures from all the annual reports are shown on this page. The documents themselves (PDF and XBRL, the machine-readable edition) are downloaded with a Pro account: sign in or create a free account, and then choose Pro. XBRL is the edition the figures on the page are read from.
Employees
monthly figures from CVRPosition in the industry
59 companies in the databaseComparison with the other companies in manufacture of pharmaceutical preparations based on the latest financial year.
Gross profitDKK 23.1mNo. 19 of 57
Better than 68% of the companies in the industry
EquityDKK 36.2mNo. 20 of 59
Better than 67% of the companies in the industry
Number of employees13No. 33 of 59
Better than 45% of the companies in the industry
Industry median: gross profit DKK 2.8m, net profit −DKK 2.2m, equity DKK 5.2m, 10 employees.
Compared with similar companies
size, age and company form| Group | Gross profit | Equity |
|---|---|---|
| Companies with fewer than 20 employees69,967 companies in the comparison | No. 1,220of 69,742 Better than 98% | No. 3,918of 69,964 Better than 94% |
| Same industry and fewer than 20 employees37 companies in the comparison | No. 5of 36 Better than 89% | No. 5of 37 Better than 89% |
| Companies that are between 5 and 14 years old33,688 companies in the comparison | No. 1,724of 33,588 Better than 95% | No. 1,530of 33,687 Better than 95% |
| All companies of type A/S18,025 companies in the comparison | No. 5,335of 17,786 Better than 70% | No. 4,412of 18,024 Better than 76% |
The rank is calculated among companies in the database with a figure for the latest financial year, and is shown only for groups of at least ten companies.
Compare with the industry
Manufacture of pharmaceutical preparationsGross profit
- Afyx Therapeutics A/SDKK 23.1m
- Novo Nordisk A/SDKK 250.3bn
- H. Lundbeck A/SDKK 20.4bn
Net profit
- Afyx Therapeutics A/SDKK 1.5m
- Novo Nordisk A/SDKK 102.4bn
- H. Lundbeck A/SDKK 3.2bn
Equity
- Afyx Therapeutics A/SDKK 36.2m
- Novo Nordisk A/SDKK 194bn
- H. Lundbeck A/SDKK 24.9bn
Employees
- Afyx Therapeutics A/S13
- Novo Nordisk A/S27,279
- H. Lundbeck A/S2,261
Latest financial year per company. Choose up to three companies from the largest in the industry.
Owners and group
from the Public Ownership RegisterOwners
- Afyx Capital ApS66.67%
Afyx Therapeutics A/S
Management
5 active registrationsExecutive management
| Name | Role | Appointed |
|---|---|---|
| Claus Juan Møller-San Pedro | CEO | 07/09/2023 |
Board of directors
| Name | Role | Appointed |
|---|---|---|
| Ole Baadsgaard | Chair of the board | 21/12/2023 |
| Claus Juan Møller-San Pedro | Board member | 21/12/2023 |
| Pia Leah Møller-San Pedro | Board member | 21/12/2023 |
| Søren Mohrsen Kjær | Board member | 03/04/2024 |
- Founders
- Juuz ApS, Afyx Capital ApS
Former management (7)
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| Søren Anker Nielsen | CEO | 12/07/2017 | 14/08/2017 |
| Søren Anker Nielsen | Chair of the board | 12/07/2017 | 22/03/2023 |
| Richard Henry Poulsen | CEO | 14/08/2017 | 06/10/2021 |
| Richard Henry Poulsen | Director | 07/10/2021 | 23/03/2023 |
| Søren Anker Nielsen | CEO | 07/10/2021 | 07/09/2023 |
| Claus Juan Møller-San Pedro | Chair of the board | 23/03/2023 | 20/12/2023 |
| Søren Anker Nielsen | Board member | 23/03/2023 | 07/09/2023 |
Signing rule: Selskabet tegnes af den samlede bestyrelse eller af selskabets administrerende direktør og et medlem af bestyrelsen i forening.
Address and production units
1 active production unitsSlotsmarken 11
2970 Hørsholm
Hørsholm Municipality · Postcode 2970
Other companies at the address (1)
- M&e Engineering A/SEngineering consultancy in construction and civil engineering
| Production unit | Address | Employees | P number |
|---|---|---|---|
| Afyx Therapeutics A/S | Slotsmarken 11, 2970 Hørsholm | 11 | 1022659436 |
Purpose
Selskabets formål er at foretage salg og udvikling af lægemidler, behandlinger og medicinsk udstyr til brug globalt, samt andre aktiviteter der står i forbindelse hermed.
The purpose is quoted from the register in Danish.
Changes year by year
98 registered events142017
52018
92019
92020
122021
12022
282023
182024
12025
12026
20261 changeaccounts 1
- AccountsAnnual report for 2025 published
20251 changeaccounts 1
- AccountsAnnual report for 2024 published
202418 changesaddress 1 · capital 3 · ownership 11 · accounts 1 · name 1 · management 1
- AddressMoved to Slotsmarken 11, 2970 Hørsholm
- CapitalShare capital changed from 18,831,752 DKK to 20,008,777 DKK
- OwnershipSPEXMAC HOLDING ApS is no longer registered as owner
- OwnershipJUUZ ApS is no longer registered as owner
- OwnershipAfyx Capital ApS registered as owner (66.67%)
- OwnershipAfyx Capital ApS is no longer registered as owner
- OwnershipSPEXMAC HOLDING ApS registered as owner (5%)
- CapitalShare capital changed from 18,266,800 DKK to 18,831,752 DKK
- OwnershipINVESTERINGSSELSKABET GH ApS is no longer registered as owner
- AccountsAnnual report for 2023 published
- NameName changed from Inphena A/S to Afyx Therapeutics A/S
- ManagementSøren Mohrsen Kjær appointed board member
- CapitalShare capital changed from 4,566,700 DKK to 18,266,800 DKK
- OwnershipJUUZ ApS registered as owner (5%)
- OwnershipINVESTERINGSSELSKABET GH ApS registered as owner (5%)
- OwnershipAfyx Capital ApS registered as owner (66.67%)
- OwnershipAfyx Capital ApS is no longer registered as owner
- OwnershipJUUZ ApS is no longer registered as owner
202328 changesname 1 · management 11 · accounts 1 · capital 2 · ownership 13
- NameName changed from Inphena ApS to Inphena A/S
- ManagementPia Leah Møller-San Pedro appointed board member
- ManagementClaus Juan Møller-San Pedro appointed board member
- ManagementOle Baadsgaard appointed chair of the board
- ManagementClaus Juan Møller-San Pedro stepped down as chair of the board
- ManagementClaus Juan Møller-San Pedro appointed ceo
- ManagementSøren Anker Nielsen stepped down as board member
- ManagementSøren Anker Nielsen stepped down as ceo
- AccountsAnnual report for 2022 published
- CapitalShare capital changed from 3,566,700 DKK to 4,566,700 DKK
- ManagementSøren Anker Nielsen appointed board member
- ManagementClaus Juan Møller-San Pedro appointed chair of the board
- ManagementRichard Henry Poulsen stepped down as director
- OwnershipINVESTERINGSSELSKABET GH ApS registered as owner (20%)
- OwnershipINVESTERINGSSELSKABET GH ApS is no longer registered as owner
- OwnershipAfyx Capital ApS registered as owner (50%)
- CapitalShare capital changed from 1,205,700 DKK to 3,566,700 DKK
- ManagementSøren Anker Nielsen stepped down as chair of the board
- OwnershipJUUZ ApS registered as owner (25%)
- OwnershipAfyx Capital ApS registered as owner (50%)
- OwnershipAfyx Capital ApS is no longer registered as owner
- OwnershipINVESTERINGSSELSKABET GH ApS registered as owner (5%)
- OwnershipINVESTERINGSSELSKABET GH ApS is no longer registered as owner
- OwnershipBo Kruse is no longer registered as owner
- OwnershipSøren Anker Nielsen is no longer registered as owner
- OwnershipINVESTERINGSSELSKABET GH ApS is no longer registered as owner
- OwnershipJUUZ ApS is no longer registered as owner
- OwnershipAfyx Capital ApS is no longer registered as owner
20221 changeaccounts 1
- AccountsAnnual report for 2021 published
202112 changesmanagement 3 · ownership 8 · accounts 1
- ManagementSøren Anker Nielsen appointed ceo
- ManagementRichard Henry Poulsen appointed director
- OwnershipINVESTERINGSSELSKABET GH ApS registered as owner (5%)
- OwnershipJUUZ ApS registered as owner (25%)
- OwnershipBo Kruse registered as owner (5%)
- OwnershipSøren Anker Nielsen registered as owner (25%)
- ManagementRichard Henry Poulsen stepped down as ceo
- OwnershipSøren Anker Nielsen is no longer registered as owner
- OwnershipBo Kruse is no longer registered as owner
- OwnershipJUUZ ApS is no longer registered as owner
- OwnershipINVESTERINGSSELSKABET GH ApS is no longer registered as owner
- AccountsAnnual report for 2020 published
20209 changescapital 1 · ownership 8
- CapitalShare capital changed from 813,700 DKK to 1,205,700 DKK
- OwnershipAfyx Capital ApS registered as owner (50%)
- OwnershipSøren Anker Nielsen registered as owner (15%)
- OwnershipBo Kruse registered as owner (15%)
- OwnershipJUUZ ApS registered as owner (15%)
- OwnershipINVESTERINGSSELSKABET GH ApS registered as owner (15%)
- OwnershipAfyx Capital ApS is no longer registered as owner
- OwnershipINVESTERINGSSELSKABET GH ApS is no longer registered as owner
- OwnershipJUUZ ApS is no longer registered as owner
20199 changescapital 2 · ownership 7
- CapitalShare capital changed from 731,000 DKK to 813,700 DKK
- CapitalShare capital changed from 418,500 DKK to 731,000 DKK
- OwnershipAfyx Capital ApS registered as owner (33.33%)
- OwnershipINVESTERINGSSELSKABET GH ApS registered as owner (25%)
- OwnershipJUUZ ApS registered as owner (25%)
- OwnershipRichard Henry Poulsen is no longer registered as owner
- OwnershipINVESTERINGSSELSKABET GH ApS is no longer registered as owner
- OwnershipAfyx Capital ApS is no longer registered as owner
- OwnershipJUUZ ApS is no longer registered as owner
20185 changesownership 2 · capital 2 · address 1
- OwnershipRichard Henry Poulsen registered as owner (5%)
- OwnershipMichael Rimikis is no longer registered as owner
- CapitalShare capital changed from 243,500 DKK to 418,500 DKK
- AddressMoved to Agern Alle 24, 2970 Hørsholm
- CapitalShare capital changed from 162,500 DKK to 243,500 DKK
201714 changescapital 1 · ownership 8 · management 4 · founded 1
- CapitalShare capital changed from 100,000 DKK to 162,500 DKK
- OwnershipINVESTERINGSSELSKABET GH ApS registered as owner (25%)
- OwnershipMichael Rimikis registered as owner (5%)
- OwnershipAfyx Capital ApS registered as owner (25%)
- OwnershipJUUZ ApS registered as owner (25%)
- OwnershipAfyx Capital ApS is no longer registered as owner
- OwnershipJUUZ ApS is no longer registered as owner
- ManagementRichard Henry Poulsen appointed ceo
- ManagementSøren Anker Nielsen stepped down as ceo
- FoundedRegistered as Inphena ApS
- ManagementSøren Anker Nielsen appointed ceo
- ManagementSøren Anker Nielsen appointed chair of the board
- OwnershipAfyx Capital ApS registered as owner (50%)
- OwnershipJUUZ ApS registered as owner (50%)
Related companies
Same industry in Hørsholm
- Repoceuticals A/S2 employees
- Reponex Pharmaceuticals A/S2 employees
Same people in management
- Genmab A/Svia Bo Kruse
- Capio A/Svia Claus Juan Møller-San Pedro
- Y-mAbs Therapeutics A/Svia Bo Kruse
- Eye-go A/Svia Søren Anker Nielsen
- Rosco Diagnostica ApSvia Søren Anker Nielsen
- K/S Varberg Hotelopsparingvia Claus Juan Møller-San Pedro
Largest in the industry
- Novo Nordisk A/SDKK 250.3bn
- H. Lundbeck A/SDKK 20.4bn
- Leo Pharma A/SDKK 8.2bn
- Alk-abelló A/SDKK 4.2bn
- Bavarian Nordic A/SDKK 3bn
- Pharmacosmos A/SDKK 1.6bn
Source and updates
The information comes from the Danish Central Business Register (Danish Business Authority) and from annual reports filed with the Danish Business Authority. Last synchronised 24/10/2026. The company is protected against advertising; contact details are not shown, and the data must not be used for marketing.